http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011330868-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29e8cd4c9c3b8b9bede3e859946c30e5
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
filingDate 2011-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b69963fe76b4ad238f5660b58085947c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7aad1f60bfd4ef0441d605c2cca7801
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f5cecf2432da1e8c8004db8cd7c6713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30bc2972a9104e7400c45404030abb6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_561a211534608cb76f03c83466e84f71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfd967b58301e18dcbcf0e4b1f2ffd70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40f834f7f63881be93d46d32f05fa16d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_748be2de93b23b5815dc2f8006b63d82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1498dad00a8b91d8c75dca067c69f0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a080aca129ecf4db8b4f02f61b7cb214
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acedab72b4be32848456ea76d061a3e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b268973acf3641d1934e40dca397aae9
publicationDate 2013-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2011330868-A1
titleOfInvention Crystalline pharmaceutically active ingredients
abstract The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis.
priorityDate 2010-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506512
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451326926
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53486317
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60823
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID29918986
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419517945
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419574452
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282455
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413649047
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426152218
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409060395
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452336560
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID446157
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24424
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450470952
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559351
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87944780
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70705
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14798
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID32051
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451953739
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9920342

Total number of triples: 55.